Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Immunomedics, Inc.    IMMU   US4529071080


SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

04/01/2013 | 06:11pm US/Eastern
   By Kristin Jones 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
Recommend :
React to this article
Latest news on IMMUNOMEDICS, INC.
1d ago IMMUNOMEDICS : Highlights Clinical Pipeline for Solid Cancer and Lupus Therapy a..
2d ago NASDAQ OMX : Immunomedics, Inc. to Ring The NASDAQ Stock Market Opening Bell
3d ago IMMUNOMEDICS : Assigned Patent
04/10 IMMUNOMEDICS : UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action I..
04/10 IMMUNOMEDICS : to Ring Opening Bell and Host R&D Day at the NASDAQ Stock Market
04/08 IMMUNOMEDICS : INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Pla..
04/08 IMMUNOMEDICS : Reports Preclinical Results on SN-38 Antibody-Drug Conjugates as ..
04/07 IMMUNOMEDICS : Reports Results From Three Phase I Trials With IMMU-130 in Metast..
04/07 IMMUNOMEDICS : Announces Multiple Partial Responses With IMMU-132 in Solid Cance..
03/31 IMMUNOMEDICS : to Provide Clinical Trial Updates on Solid-Tumor Antibody-Drug Co..
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Income Statement Evolution
Immunomedics, Inc. : Income Statement Evolution
More Financials
Dynamic quotes